Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology (CRDF) Income Statement


Cardiff Oncology Income Statement

Last quarter (Q4 2023), Cardiff Oncology's total revenue was $156.00K, an increase of 21.88% from the same quarter last year. In Q4, Cardiff Oncology's net income was $-9.34M. See Cardiff Oncology’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 488.00K$ 488.00K$ 386.00K$ 359.00K$ 366.00K$ 244.63K
Cost of Revenue
-----$ 0.00
Gross Profit
$ 488.00K$ 488.00K$ 386.00K$ 359.00K-$ 244.63K
Operating Expense
$ 45.90M$ 45.90M$ 40.29M$ -29.21M$ 19.45M$ 16.92M
Operating Income
$ -45.41M$ -45.41M$ -39.90M$ -28.86M$ -19.09M$ -16.68M
Net Non Operating Interest Income Expense
$ 4.07M$ 4.07M$ 1.58M$ 264.00K$ 88.00K$ 234.17K
Other Income Expense
$ 98.00K$ 98.00K$ 383.00K$ -300.00K$ -309.00K$ 30.17K
Pretax Income
$ -41.44M$ -41.44M$ -38.70M$ -28.29M$ -19.31M$ -16.41M
Tax Provision
$ -9.09M$ -9.09M$ -518.00K$ -72.00K--
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -41.47M$ -41.47M$ -38.73M$ -28.32M$ -22.60M$ -16.71M
Basic EPS
$ -0.93$ -0.93$ -0.89$ -0.73$ -1.08$ -2.80
Diluted EPS
$ -0.93$ -0.93$ -0.89$ -0.73$ -1.08$ -2.80
Basic Average Shares
$ 178.71M$ 44.68M$ 43.60M$ 39.03M$ 20.87M$ 5.97M
Diluted Average Shares
$ 178.71M$ 44.68M$ 43.60M$ 39.03M$ 20.87M$ 5.97M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 45.90M$ 45.90M$ 40.29M$ -29.21M$ 19.45M$ 16.92M
Net Income From Continuing And Discontinued Operation
$ -41.44M$ -41.44M$ -38.70M$ -28.29M$ -19.31M$ -16.41M
Normalized Income
$ -34.92M$ -50.53M$ -39.22M-$ -19.03M$ -16.44M
Interest Expense
----$ 2.00K$ 0.00
$ -41.44M$ -41.44M$ -38.70M$ -28.29M$ -19.30M$ -16.41M
$ -41.96M$ -41.96M$ -37.84M$ -26.23M$ -18.84M$ -15.92M
Currency in USD

Cardiff Oncology Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis